ReviewCurrent opinion in immunology2021
Adverse events induced by immune checkpoint inhibitors.
Review in Current opinion in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 3 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Efficacy and safety of immunotherapy in anaplastic thyroid carcinoma: a systematic review and meta-analysis.International journal of surgery (London, England) · 2026Pooled it
- Efficacy and safety of immune checkpoint inhibitors for locoregionally advanced, recurrent and metastatic nasopharyngeal carcinoma: a systematic review of phase III randomised controlled trials.Naunyn-Schmiedeberg's archives of pharmacology · 2026Pooled it
- Before-treatment body mass index as a prognostic factor in cancer patients receiving immune checkpoint inhibitors: a systematic review and dose-response meta-analysis.Frontiers in immunology · 2026Pooled it
- Review
- B cell-driven refractory hemocytopenia in immune checkpoint inhibitor therapy: a report of two cases.Translational lung cancer research · 2026Article
- Predicting checkpoint inhibitor-associated autoimmune diabetes: prospects and limitations.The Journal of clinical investigation · 2026Article
- Optimizing anti-PI3Kδ and anti-LAG-3 immunotherapy dosing regimens in a mouse model of triple-negative breast cancer improves outcome by removing treatment-related adverse events.Journal for immunotherapy of cancer · 2026Article
- Molecular classification and immunotherapy in fertility-sparing treatment for endometrial cancer: opportunities and challenges.Frontiers in oncology · 2026Review
- Clinical characteristics of immune-related adverse events after immune checkpoint inhibitor therapy with or without chemotherapy in patients with antinuclear antibody-positive malignancies.Frontiers in immunology · 2026Article
- Severe Immune-Related Adverse Events Associated with Durable Antitumor Responses Following Immune Checkpoint Inhibitor Therapy: Two Case Reports.Cancer management and research · 2026Article
- Case report and literature review: isolated ACTH deficiency induced by combined nivolumab and trastuzumab therapy in gastric adenocarcinoma.Frontiers in endocrinology · 2026Review
- Hematologic immune-related adverse effects of immune checkpoint inhibitors: a review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Review
- Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes.Journal for immunotherapy of cancer · 2025Article
- Arteritic anterior ischemic optic neuropathy secondary to immune checkpoint inhibitors: A case report.Radiology case reports · 2025Article
- Cemiplimab-Induced Colitis Causing Hypovolemic Shock: A Case Report and Literature Review.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- Immune-related adverse events in older adults receiving immune checkpoint inhibitors: a comprehensive analysis of the Food and Drug Administration Adverse Event Reporting System.Age and ageing · 2025Article
- Deciphering T-cell exhaustion in the tumor microenvironment: paving the way for innovative solid tumor therapies.Frontiers in immunology · 2025Review
- Tertiary Lymphoid Structures and Immunotherapy: Challenges and Opportunities.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Resveratrol alleviates testicular toxicity induced by anti-PD-1 through regulating the NRF2-SLC7A11-GPX4 pathway.Frontiers in immunology · 2025Article
- Advances in the mechanisms, imaging characteristics and management strategies for immune checkpoint inhibitor-related pneumonitis.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Immune checkpoint inhibitors have revolutionized the treatments of cancers but are also associated with immune related adverse events that can interfere with their use. The types and severity of adverse events vary with checkpoint inhibitors. A single mechanism of pathogenesis has not emerged: postulated mechanisms involve direct effects of the checkpoint inhibitor, emergence of autoantibodies or autoreactive T cells, and destruction by toxic effects of activated T cells. Several host factors such as genotypes, preexisting autoimmune disease, inflammatory responses and others may have predictive value. Ongoing investigations seek to identify ways of modulating the autoimmunity without affecting the anti-tumor response with agents that are specific for the autoimmune mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.